Reference(s)
Click here to return to the Reference Table

Descriptor: Therapeutic Development


Acute Myelogenous Leukemia

Adult T Cell Leukemia

Reference Number: 516
Choi YL, Tsukasaki K, O'Neill MC, Yamada Y, Onimaru Y, Matsumoto K, Ohashi J, Yamashita Y, Tsutsumi S, Kaneda R, Takada S, Aburatani H, Kamihira S, Nakamura T, Tomonaga M, Mano H. A genomic analysis of adult T-cell leukemia. Oncogene. 26, 1245-55 (2007)
PubMed link      E-mail link

Bladder

Reference Number: 549
Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle. 6, 1393-402 (2007)
PubMed link      E-mail link

Reference Number: 715
Arena S, Pisacane A, Mazzone M, Comoglio PM, Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A. 104, 11412-7 (2007)
PubMed link      E-mail link

Reference Number: 853
Bhuvaneswari R, Gan YY, Lucky SS, Chin WW, Ali SM, Soo KC, Olivo M. Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy. Mol Cancer. 7, 56 (2008)
PubMed link      E-mail link

Reference Number: 1183
Sun B, Liu R, Xiao ZD, Zhu X. c-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS One. 7, e30143 (2012)
PubMed link      E-mail link

Reference Number: 1594
McNeil BK, Sorbellini M, Grubb RL 3rd, Apolo A, Cecchi F, Athauda G, Cohen B, Giubellino A, Simpson H, Agarwal PK, Coleman J, Getzenberg RH, Netto GJ, Shih J, Linehan WM, Pinto PA, Bottaro DP Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder. J Transl Med. 12, 199 (2014)
PubMed link      E-mail link

Reference Number: 1647
Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib. JAMA Dermatol. 151, 170-7 (2015)
PubMed link      E-mail link

Reference Number: 1771
Dang Q, Song W, Xu D, Ma Y, Li F, Zeng J, Zhu G, Wang X, Chang LS, He D, Li L. Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis. Mol Carcinog. 54, 831-40 (2015)
PubMed link      E-mail link

Breast

Reference Number: 22
Jakubczak, J. L., LaRochelle, W. J. & Merlino, G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol Cell Biol 18, 1275-83. (1998).
PubMed link      E-mail link

Reference Number: 23
Kuba, K. et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60, 6737-43 (2000).
PubMed link      E-mail link

Reference Number: 222

Martin, T.A. et al. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 24:1317-23 (2003).


PubMed link      E-mail link

Reference Number: 235
Jiang, WG, Grimshaw, D, Martin, TA, Davies, G, Parr, C, Watkins, G, Lane, J, Abounader, R, Laterra, J, Mansel, RE. Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clin Cancer Res 15:4274-81 (2003).
PubMed link      E-mail link

Reference Number: 294
Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73 (2004)
PubMed link      E-mail link

Reference Number: 295
Wright TG, Tsai J, Jia Z, Elliott BE. Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function. J Biol Chem 279, 32499-506 (2004)
PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 404
Bigelow RL, Cardelli JA. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene. 25, 1922-30 (2006)
PubMed link      E-mail link

Reference Number: 499
Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther. 6, 561-70 (2007)
PubMed link      E-mail link

Reference Number: 511
Parr C, Jiang WG. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer. 119, 1176-83 (2006)
PubMed link      E-mail link

Reference Number: 545
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res67, 4408-17 (2007)
PubMed link      E-mail link

Reference Number: 675
Yin YL, Chen HL, Kuo HM, He SP. NK3 and NK4 of HGF enhance filamin production via STAT pathway, but not NK1 and NK2 in human breast cancer cells. Acta Pharmacol Sin. 29, 728-35 (2008)
PubMed link      E-mail link

Reference Number: 676
Syed DN, Afaq F, Sarfaraz S, Khan N, Kedlaya R, Setaluri V, Mukhtar H. Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation. Toxicol Appl Pharmacol. 231, 52-60 (2008)
PubMed link      E-mail link

Reference Number: 923
Hochgräfe F, Zhang L, O'Toole SA, Browne BC, Pinese M, Porta Cubas A, Lehrbach GM, Croucher DR, Rickwood D, Boulghourjian A, Shearer R, Nair R, Swarbrick A, Faratian D, Mullen P, Harrison DJ, Biankin AV, Sutherland RL, Raftery MJ, Daly RJ. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res. 70, 9391-40 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1107
Elnagar AY, Sylvester PW, El Sayed KA. (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med. 77, 1013-9 (2011)
PubMed link      E-mail link

Reference Number: 1154
Kim EJ, Eom SJ, Hong JE, Lee JY, Choi MS, Park JH. Benzyl isothiocyanate inhibits basal and hepatocyte growth factor-stimulated migration of breast cancer cells. Mol Cell Biochem. 359, 431-40 (2012)
PubMed link      E-mail link

Reference Number: 1158
Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320, 48-55 (2012)
PubMed link      E-mail link

Reference Number: 1306
Stein GY, Yosef N, Reichman H, Horev J, Laser-Azogui A, Berens A, Resau J, Ruppin E, Sharan R, Tsarfaty I. Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival. PLoS One. 7, e45969 (2012)
PubMed link      E-mail link

Reference Number: 1355
Mehta RR1, Katta H, Kalra A, Patel R, Gupta A, Alimirah F, Murillo G, Peng X, Unni A, Muzzio M, Mehta RG. Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells. Clin Exp Metastasis. 30, 855-66 (2013)
PubMed link      E-mail link

Reference Number: 1401
Gujral TS1, Karp RL, Finski A, Chan M, Schwartz PE, MacBeath G, Sorger P. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene. 32, 3470-6 (2013)
PubMed link      E-mail link

Reference Number: 1450
Previdi S1, Scolari F, Chilà R, Ricci F, Abbadessa G, Broggini M. Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model. PLoS One. 8, e79101 (2013)
PubMed link      E-mail link

Reference Number: 1466
Mehta R, Katta H, Alimirah F, Patel R, Murillo G, Peng X, Muzzio M, Mehta RG. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells. PLoS One. 8, e65113 (2013)
PubMed link      E-mail link

Reference Number: 1523
Nicastro HL, Firestone GL, Bjeldanes LF. 3,3'-diindolylmethane rapidly and selectively inhibits hepatocyte growth factor/c-Met signaling in breast cancer cells. J Nutr Biochem. 24, 1882-8 (2013)
PubMed link      E-mail link

Reference Number: 1571
Hyuga S, Hyuga M, Yoshimura M, Amakura Y, Goda Y, Hanawa T. Herbacetin, a constituent of ephedrae herba, suppresses the HGF-induced motility of human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation. Planta Med. 79, 1525-30 (2013)
PubMed link      E-mail link

Reference Number: 1628
Akl MR, Ayoub NM, Mohyeldin MM, Busnena BA, Foudah AI, Liu YY, Sayed KA. Olive phenolics as c-Met inhibitors: (-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS One. 9, e97622 (2014)
PubMed link      E-mail link

Reference Number: 1642
Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW1, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 74, 4822-35 (2014)
PubMed link      E-mail link

Cervical

Reference Number: 398
Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, Ho CL. The significance of prohibitin and c-Met/hepatocyte growth factor receptor in the progression of cervical adenocarcinoma. Hum Pathol. 37, 198-204. Epub 2005 Dec 20 (2006)
PubMed link      E-mail link

Reference Number: 1316
Kina S, Phonaphonh T, Liang F, Kuang H, Arasaki A, Arakaki K, Nakasone T, Sunakawa H. PDGF a receptor is a mediator for Cisplatin-induced Met expression. Eur J Pharmacol. 699, 227-32 (2013)
PubMed link      E-mail link

Cholangiocarcinoma

Reference Number: 671
Socoteanu MP, Mott F, Alpini G, Frankel AE. c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol. 14, 2990-4 (2008)
PubMed link      E-mail link

Reference Number: 1315
Ge X, Wang Y, Wang Y, Li Q, Yu H, Miao L. NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells. Dig Dis Sci. 58, 1636-43 (2013)
PubMed link      E-mail link

Reference Number: 1405
Ge X1, Wang Y, Li Q, Yu H, Ji G, Miao L. NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. Oncol Rep. 30, 448-54 (2013)
PubMed link      E-mail link

Chronic Myeloid Leukemia

Reference Number: 1276
Cerny-Reiterer S, Ghanim V, Hoermann G, Aichberger KJ, Herrmann H, Muellauer L, Repa A, Sillaber C, Walls AF, Mayerhofer M, Valent P. Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression. Neoplasia. 14, 572-84 (2012)
PubMed link      E-mail link

Reference Number: 1278
Fialin C, Larrue C, Vergez F, Sarry JE, Bertoli S, Mansat-De Mas V, Demur C, Delabesse E, Payrastre B, Manenti S, Roche S, Récher C. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors. Leukemia. 27, 325-35 (2013)
PubMed link      E-mail link

Colorectal

Reference Number: 38
Fazekas, K., Raso, E., Zarandi, M., Dudas, J. & Timar, J. Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models. Anticancer Res 22, 2575-9 (2002).
PubMed link      E-mail link

Reference Number: 218
Herynk, M.H. et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.  Cancer Res 63:2990-6 (2003).
PubMed link      E-mail link

Reference Number: 299
Kubota T, Fujiwara H, Amaike H, Takashima K, Inada S, Atsuji K, Yoshimura M, Matsumoto K, Nakamura T, Yamagishi H. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. Cancer Sci 95, 321-7 (2004)
PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 618
Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther. 6, 2868-78 (2007)
PubMed link      E-mail link

Reference Number: 703
Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL, Dussault I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 68, 6680-7 (2008)
PubMed link      E-mail link

Reference Number: 715
Arena S, Pisacane A, Mazzone M, Comoglio PM, Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A. 104, 11412-7 (2007)
PubMed link      E-mail link

Reference Number: 800
Larsen CA, Dashwood RH. (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch Biochem Biophys. 501, 52-7 (2010)
PubMed link      E-mail link

Reference Number: 877
Larsen CA, Dashwood RH. Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide. Biochem Biophys Res Commun. 389, 527-30 (2009)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 972
Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res. 17, 472-82 (2011)
PubMed link      E-mail link

Reference Number: 1067
Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma. Am J Pathol. 179, 3032-44 (2011)
PubMed link      E-mail link

Reference Number: 1109
Yamaji N, Ido A, Moriuchi A, Numata M, Setoyama H, Tamai T, Funakawa K, Fujita H, Sakiyama T, Uto H, Oketani M, Tsubouchi H. Hepatocyte growth factor ameliorates mucosal injuries leading to inhibition of colon cancer development in mice. Oncol Rep. 26, 335-41 (2011)
PubMed link      E-mail link

Reference Number: 1158
Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320, 48-55 (2012)
PubMed link      E-mail link

Reference Number: 1159
Han SY, Lee CO, Ahn SH, Lee MO, Kang SY, Cha HJ, Cho SY, Ha JD, Ryu JW, Jung H, Kim HR, Koh JS, Lee J. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs. 30, 518-23 (2012)
PubMed link      E-mail link

Reference Number: 1388
Gibbons AV1, Lin JE, Kim GW, Marszalowicz GP, Li P, Stoecker BA, Blomain ES, Rattan S, Snook AE, Schulz S, Waldman SA. Intestinal GUCY2C prevents TGF-ß secretion coordinating desmoplasia and hyperproliferation in colorectal cancer. Cancer Res. 73, 6654-66 (2013)
PubMed link      E-mail link

Reference Number: 1397
Gao W1, Bing X, Li M, Yang Z, Li Y, Chen H. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma. Med Oncol. 30, 546 (2013)
PubMed link      E-mail link

Reference Number: 1436
Bendell JC1, Ervin TJ, Gallinson D, Singh J, Wallace JA, Saleh MN, Vallone M, Phan SC, Hack SP. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 12, 218-22 (2013)
PubMed link      E-mail link

Reference Number: 1470
Gao SH, Liu C, Wei J, Feng Y. Effect of c-Met inhibitor SU11274 on human colon cancer cell growth. Chin Med J (Engl). 126, 2705-9 (2013)
PubMed link      E-mail link

Reference Number: 1550
Yao YL, Shao J, Zhang C, Wu JH, Zhang QH, Wang JJ, Zhu W. Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS One. 8, e78086 (2013)
PubMed link      E-mail link

Reference Number: 1657
Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 7, 1940-55 (2014)
PubMed link      E-mail link

Reference Number: 1658
Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 136, 1967-75 (2015)
PubMed link      E-mail link

Reference Number: 1765
Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res. 20, 4240-50 (2014)
PubMed link      E-mail link

Reference Number: 1833
Sun Y, Sun L, An Y, Shen X. Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model. Med Sci Monit. 21, 2316-21 (2015)
PubMed link      E-mail link

Reference Number: 1886
Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJ, van Doorn L, Hellemans P, de Bono JS, Eskens FA. The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 21, 2297-304 (2015)
PubMed link      E-mail link

Endometrial

Reference Number: 715
Arena S, Pisacane A, Mazzone M, Comoglio PM, Bardelli A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci U S A. 104, 11412-7 (2007)
PubMed link      E-mail link

Esophogeal

Reference Number: 486
Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliveira PE, Gooding WE, Christensen JG, Hughes SJ. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia. 8, 949-55 (2006)
PubMed link      E-mail link

Reference Number: 642
Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 98, 1102-8 (2008)
PubMed link      E-mail link

Reference Number: 1024
Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 29, 4803-10 (2011)
PubMed link      E-mail link

Reference Number: 1054
Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Sanicola M, Henderson L, Grushko TA, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes E, Frank DA, Kindler HL, Huet H, Salgia R. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 12, 9-46 (2011)
PubMed link      E-mail link

Reference Number: 1395
Boland PM1, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock? Curr Opin Oncol. 25, 417-24 (2013)
PubMed link      E-mail link

Reference Number: 1460
Forde PM, Kelly RJ. Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies. Oncologist. 18, 823-32 (2013)
PubMed link      E-mail link

Reference Number: 1634
Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget. 5, 2866-80 (2014)
PubMed link      E-mail link

Gastric

Reference Number: 47
Hirao, S. et al. Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. Cancer Gene Ther 9, 700-7 (2002).
PubMed link      E-mail link

Reference Number: 48
Morotti, A., Mila, S., Accornero, P., Tagliabue, E. & Ponzetto, C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21, 4885-93 (2002).
PubMed link      E-mail link

Reference Number: 316
Heideman DA, van Beusechem VW, Bloemena E, Snijders PJ, Craanen ME, Offerhaus GJ, Derksen PW, de Bruin M, Witlox MA, Molenaar B, Meijer CJ, Gerritsen WR. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. J Gene Med 6, 317-27 (2004)
PubMed link      E-mail link

Reference Number: 334
Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Yatomi Y, Nagawa H. Sphingosine 1-phosphate transactivates c-Met as well as epidermal growth factor receptor (EGFR) in human gastric cancer cells. FEBS Lett. 577, 333-8 (2004)
PubMed link      E-mail link

Reference Number: 343
Ueda K, Iwahashi M, Matsuura I, Nakamori M, Nakamura M, Ojima T, Naka T, Ishida K, Matsumoto K, Nakamura T, Yamaue H. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur J Cancer  40, 2135-42 (2004)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 948
Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L. Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res. 16, 3933-43 (2010)
PubMed link      E-mail link

Reference Number: 949
Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res. 70, 7580-90 (2010)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 974
Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 25, 1517-24 (2011)
PubMed link      E-mail link

Reference Number: 1004
Guo T, Zhu Y, Gan CS, Lee SS, Zhu J, Wang H, Li X, Christensen J, Huang S, Kon OL, Sze SK. Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells. Mol Cell Proteomics. 9, 2629-41 (2010)
PubMed link      E-mail link

Reference Number: 1024
Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 29, 4803-10 (2011)
PubMed link      E-mail link

Reference Number: 1175
Ryu JW, Han SY, Yun JI, Choi SU, Jung H, Ha JD, Cho SY, Lee CO, Kang NS, Koh JS, Kim HR, Lee J. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors. Bioorg Med Chem Lett. 21, 7185-8 (2011)
PubMed link      E-mail link

Reference Number: 1205
Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther. 11, 660-9 (2012)
PubMed link      E-mail link

Reference Number: 1219
Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 30, 1352-60 (2012)
PubMed link      E-mail link

Reference Number: 1241
Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 11, 1557-64 (2012)
PubMed link      E-mail link

Reference Number: 1242
Kneissl J, Keller S, Lorber T, Heindl S, Keller G, Drexler I, Hapfelmeier A, Höfler H, Luber B. Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. Int J Oncol. 41, 733-44 (2012)
PubMed link      E-mail link

Reference Number: 1261
Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Cancer Lett. 332, 74-82 (2013)
PubMed link      E-mail link

Reference Number: 1280
Feng Y, Ma PC. Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer. Cancer Discov. 1, 550-4 (2011)
PubMed link      E-mail link

Reference Number: 1282
Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A, Salgia R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 1, 573-9 (2011)
PubMed link      E-mail link

Reference Number: 1313
Humbert M, Medová M, Aebersold DM, Blaukat A, Bladt F, Fey MF, Zimmer Y, Tschan MP. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem Biophys Res Commun. 431, 264-9 (2013)
PubMed link      E-mail link

Reference Number: 1318
Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K, Yamada Y. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget. 4, 9-17 (2013)
PubMed link      E-mail link

Reference Number: 1347
Shah MA1, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 8, e54014 (2013)
PubMed link      E-mail link

Reference Number: 1363
Wiehr S1, von Ahsen O, Röse L, Mueller A, Mannheim JG, Honndorf V, Kukuk D, Reischl G, Pichler BJ. Preclinical evaluation of a novel c-Met inhibitor in a gastric cancer xenograft model using small animal PET. Mol Imaging Biol. 15, 203-11 (2013)
PubMed link      E-mail link

Reference Number: 1375
Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A, Xu W, Cai X, Voi M, Savagner P, Lai CJ. Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther. 12, 925-36 (2013)
PubMed link      E-mail link

Reference Number: 1376
Awazu Y, Nakamura K, Mizutani A, Kakoi Y, Iwata H, Yamasaki S, Miyamoto N, Imamura S, Miki H, Hori A. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities. Mol Cancer Ther. 12, 913-24 (2013)
PubMed link      E-mail link

Reference Number: 1382
Hong SW1, Jung KH, Lee HS, Son MK, Yan HH, Kang NS, Lee J, Hong SS. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis. 34, 2156-69 (2013)
PubMed link      E-mail link

Reference Number: 1406
Yashiro M1, Nishii T, Hasegawa T, Matsuzaki T, Morisaki T, Fukuoka T, Hirakawa K. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. Br J Cancer 109, 2619-28 (2013)
PubMed link      E-mail link

Reference Number: 1453
Yamaguchi H1, Takanashi M, Yoshida N, Ito Y, Kamata R, Fukami K, Yanagihara K, Sakai R. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors. Cancer Sci. 105, 528-36 (2014)
PubMed link      E-mail link

Reference Number: 1472
Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda M, Kiyota N, Fujiwara Y, Minami H. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest New Drugs. 31, 1158-68 (2013)
PubMed link      E-mail link

Reference Number: 1565
Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene. 33, 3334-41 (2014)
PubMed link      E-mail link

Reference Number: 1582
Kang YK, Muro K, Ryu MH, Yasui H, Nishina T, Ryoo BY, Kamiya Y, Akinaga S, Boku N. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs. 32, 355-6 (2014)
PubMed link      E-mail link

Reference Number: 1617
Meng L, Shu M, Chen Y, Yang D, He Q, Zhao H, Feng Z, Liang C, Yu K. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers. Cancer Biol Ther. 15, 721-34 (2014)
PubMed link      E-mail link

Reference Number: 1649
Funakoshi Y, Mukohara T, Ekyalongo RC, Tomioka H, Kataoka Y, Shimono Y, Chayahara N, Toyoda M, Kiyota N, Fujiwara Y, Minami H. Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells. Oncol Res. 21, 287-93 (2013)
PubMed link      E-mail link

Reference Number: 1692
Newbold A, Martin BP, Cullinane C, Bots M. Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in solid tumors. Cold Spring Harb Protoc. Oct 1;2014(10):pdb.prot082529
PubMed link      E-mail link

Reference Number: 1715
Zhu M, Tang R, Doshi S, Oliner KS, Dubey S, Jiang Y, Donehower RC, Iveson T, Loh EY, Zhang Y Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. Br J Cancer. 112, 429-37 (2015)
PubMed link      E-mail link

Reference Number: 1717
Morishita A, Gong J, Masaki T Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol. 20, 4536-45 (2014)
PubMed link      E-mail link

Reference Number: 1739
Musiani D, Konda JD, Pavan S, Torchiaro E, Sassi F, Noghero A, Erriquez J, Perera T, Olivero M, Di Renzo MF. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy. FASEB J. 28, 4055-67 (2014)
PubMed link      E-mail link

Reference Number: 1783
Egile C, Kenigsberg M, Delaisi C, Bégassat F, Do-Vale V, Mestadier J, Bonche F, Bénard T, Nicolas JP, Valence S, Lefranc C, Francesconi E, Castell C, Lefebvre AM, Nemecek C, Calvet L, Goulaouic H. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 14, 384-94 (2015)
PubMed link      E-mail link

Reference Number: 1809
Gavine PR, Ren Y, Han L, Lv J, Fan S, Zhang W, Xu W, Liu YJ, Zhang T, Fu H, Yu Y, Wang H, Xu S, Zhou F, Su X, Yin X, Xie L, Wang L, Qing W, Jiao L, Su W, Wang QM. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 9, 323-33 (2015)
PubMed link      E-mail link

Reference Number: 1812
Doshi S, Gisleskog PO, Zhang Y, Zhu M, Oliner KS, Loh E, Perez Ruixo JJ. Rilotumumab exposure-response relationship in patients with advanced or metastatic gastric cancer. Clin Cancer Res. 21, 2453-61 (2015)
PubMed link      E-mail link

Glioblastomas/Astrocytomas

Reference Number: 194
Abounader, R. et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J Natl Cancer Inst 91, 1548-56 (1999).
PubMed link      E-mail link

Reference Number: 195
Abounader, R. et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. Faseb J 16, 108-10 (2002).
PubMed link      E-mail link

Reference Number: 199
Guerin, C., Luddy, C., Abounader, R., Lal, B. & Laterra, J. Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. Biochem Biophys Res Commun 273, 287-93 (2000).
PubMed link      E-mail link

Reference Number: 269
Brockmann MA, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 9:4578-85 (2003).
PubMed link      E-mail link

Reference Number: 336
Xie Q, Gao CF, Shinomiya N, Sausville E, Hay R, Gustafson M, Shen Y, Wenkert D, Vande Woude GF. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 24, 3697-707 (2005)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 350
Lal B, Xia S, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res. 11, 4479-86 (2005)
PubMed link      E-mail link

Reference Number: 517
Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 12, 6144-52 (2006)
PubMed link      E-mail link

Reference Number: 521
Chu S, Yuan X, Li Z, Jiang P, Zhang J. C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells. Surg Neurol. 65, 533-8 (2006)
PubMed link      E-mail link

Reference Number: 522
Chu SH, Zhu ZA, Yuan XH, Li ZQ, Jiang PC. In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J Neurooncol. 80, 143-9 (2006)
PubMed link      E-mail link

Reference Number: 567
Chu SH, Zhang H, Ma YB, Feng DF, Zhu ZA, Yuan XH, Li ZQ. c-Met antisense oligodeoxynucleotides as a novel therapeutic agent for glioma: in vitro and in vivo studies of uptake, effects, and toxicity. J Surg Res. 141, 284-8 (2007)
PubMed link      E-mail link

Reference Number: 585
Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci U S A. 104, 12867-72 (2007)
PubMed link      E-mail link

Reference Number: 606
Towner RA, Smith N, Doblas S, Tesiram Y, Garteiser P, Saunders D, Cranford R, Silasi-Mansat R, Herlea O, Ivanciu L, Wu D, Lupu F. In vivo detection of c-Met expression in a rat C6 glioma model. J Cell Mol Med. 12, 174-86 (2008)
PubMed link      E-mail link

Reference Number: 607
Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A, Burgess TL. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 13, 6735-42 (2007)
PubMed link      E-mail link

Reference Number: 622
Tseng JR, Kang KW, Dandekar M, Yaghoubi S, Lee JH, Christensen JG, Muir S, Vincent PW, Michaud NR, Gambhir SS. Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 49, 129-34 (2008)
PubMed link      E-mail link

Reference Number: 703
Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL, Dussault I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res. 68, 6680-7 (2008)
PubMed link      E-mail link

Reference Number: 711
Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 66, 1721-9 (2006)
PubMed link      E-mail link

Reference Number: 859
Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 4:69 (2009)
PubMed link      E-mail link

Reference Number: 861
Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, Johnson E, Marcinkiewicz L, Engelhardt M, Kefas B, Schiff D, Kim J, Abounader R. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther. 8, 376-85 (2009)
PubMed link      E-mail link

Reference Number: 862
Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia. 11, 448-58 (2009)
PubMed link      E-mail link

Reference Number: 863
Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther. 8, 1751-60 (2009)
PubMed link      E-mail link

Reference Number: 865
Zhao P, Gao C, Dykema K, Furge K, Feng Z, Cao B. Repeated hepatocyte growth factor neutralizing antibody treatment leads to HGF/SF unresponsiveness in human glioblastoma multiforme cells. Cancer Lett. 291, 209-16 (2010)
PubMed link      E-mail link

Reference Number: 867
Guessous F, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D, Buchanan S, Abounader R. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. Anticancer Agents Med Chem. 10, 28-35 (2010)
PubMed link      E-mail link

Reference Number: 962
Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 13, 437-46 (2011)
PubMed link      E-mail link

Reference Number: 1016
Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A. 98, 7443-8 (2001)
PubMed link      E-mail link

Reference Number: 1181
Jin J, Bae KH, Yang H, Lee SJ, Kim H, Kim Y, Joo KM, Seo SW, Park TG, Nam DH. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 22, 2568-72 (2011)
PubMed link      E-mail link

Reference Number: 1214
Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van Dongen GA. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther. 11, 1017-25 (2012)
PubMed link      E-mail link

Reference Number: 1268
Yang H, Lee HW, Kim Y, Lee Y, Choi YS, Kim KH, Jin J, Lee J, Joo KM, Nam DH. Radiosensitization of brain metastasis by targeting c-MET. Lab Invest. 93, 344-53 (2013)
PubMed link      E-mail link

Reference Number: 1275
Miekus K, Kijowski J, Sekula M, Majka M. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. Oncol Rep. 28, 1903-9 (2012)
PubMed link      E-mail link

Reference Number: 1349
Zhang Y1, Farenholtz KE, Yang Y, Guessous F, Dipierro CG, Calvert VS, Deng J, Schiff D, Xin W, Lee JK, Purow B, Christensen J, Petricoin E, Abounader R. Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition. Clin Cancer Res. 19, 1433-44 (2013)
PubMed link      E-mail link

Reference Number: 1410
Lee SJ1, Seol HJ, Lee HW, Kang WY, Kang BG, Jin J, Jo MY, Jin Y, Lee JI, Joo KM, Nam DH. Gene silencing of c-Met leads to brain metastasis inhibitory effects. Clin Exp Metastasis. 30, 845-54 (2013)
PubMed link      E-mail link

Reference Number: 1503
Rex K, Lewis XZ, Gobalakrishnan S, Glaus C, Silva MD, Radinsky R, Burgess TL, Gambhir SS, Coxon A. Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model. Nucl Med Biol. 40, 458-63 (2013)
PubMed link      E-mail link

Reference Number: 1704
Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, Zhang H, James CD, Sznajder JI, Chin L, Giljohann DA, Kessler JA, Peter ME, Mirkin CA, Stegh AH. miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev. 29, 732-45 (2015)
PubMed link      E-mail link

Head and Neck

Reference Number: 224
Aebersold, D.M. et al. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 22:8519-23 (2003).
PubMed link      E-mail link

Reference Number: 655
Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki S, Quesnelle KM, Morgan S, Ferris RL, Grandis JR, Siegfried JM. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res. 15, 3740-50 (2009)
PubMed link      E-mail link

Reference Number: 667
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008 May 20. [Epub ahead of print]
PubMed link      E-mail link

Reference Number: 967
Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK, Tsang CM, Tsao SW, Cheng SH, Ng MH, Ng YK, Lam EK, Hong B, Lo KW, Mok TS, Chan AT, Mills GB. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene. 30, 1127-34 (2011)
PubMed link      E-mail link

Reference Number: 968
Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-31 (2009)
PubMed link      E-mail link

Reference Number: 988
Sen B, Peng S, Saigal B, Williams MD, Johnson FM. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res. 17, 514-24 (2011)
PubMed link      E-mail link

Reference Number: 1047
Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res. 17, 4425-38 (2011)
PubMed link      E-mail link

Reference Number: 1101
Koh YW, Choi EC, Kang SU, Hwang HS, Lee MH, Pyun J, Park R, Lee Y, Kim CH. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. J Nutr Biochem. 22, 1074-83 (2011)
PubMed link      E-mail link

Reference Number: 1287
Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol. 83, 882-93 (2013)
PubMed link      E-mail link

Reference Number: 1339
Stabile LP, He G, Lui VW, Thomas S, Henry C, Gubish CT, Joyce S, Quesnelle KM, Siegfried JM, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clin Cancer Res. 19, 380-92 (2013)
PubMed link      E-mail link

Reference Number: 1489
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 31, 3639-46 (2013)
PubMed link      E-mail link

Reference Number: 1530
Zhou Y, Zhao C, Gery S, Braunstein GD, Okamoto R, Alvarez R, Miles SA, Doan NB, Said JW, Gu J, Phillip Koeffler H. Off-target effects of c-MET inhibitors on thyroid cancer cells. Mol Cancer Ther. 13, 134-43 (2014)
PubMed link      E-mail link

Reference Number: 1842
Kumar D, Kandl C, Hamilton CD, Shnayder Y, Tsue TT, Kakarala K, Ledgerwood L, Sun XS, Huang HJ, Girod D, Thomas SM. Mitigation of Tumor-Associated Fibroblast-Facilitated Head and Neck Cancer Progression With Anti-Hepatocyte Growth Factor Antibody Ficlatuzumab. JAMA Otolaryngol Head Neck Surg. 141, 1133-9 (2015)
PubMed link      E-mail link

Reference Number: 1887
Baschnagel AM, Galoforo S, Thibodeau BJ, Ahmed S, Nirmal S, Akervall J, Wilson GD. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts. Anticancer Res. 35, 5973-82 (2015)
PubMed link      E-mail link

Kaposi's Sarcoma

Kidney

Reference Number: 340
Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, Streit B, Stalder D, Gruber G, Liang C, Howlett AR, Candinas D, Greiner RH, Lipson KE, Zimmer Y. The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23, 5387-93 (2004)
PubMed link      E-mail link

Reference Number: 634
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM, O'Connor AB, Gu Y, Coxon A, Kim TS, Tasker A, Burgess TL, Dussault I. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 283, 2675-83 (2008)
PubMed link      E-mail link

Reference Number: 686
Migliore C, Giordano S. Molecular cancer therapy: can our expectation be MET? Eur J Cancer. 44, 641-51. (2008) Epub 2008 Mar 4

PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1108
Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 108, 679-86 (2011)
PubMed link      E-mail link

Reference Number: 1274
Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 118, 5894-902 (2012)
PubMed link      E-mail link

Reference Number: 1311
Benitez A, Yates TJ, Shamaldevi N, Bowen T, Lokeshwar VB. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. J Urol. 190, 285-90 (2013)
PubMed link      E-mail link

Reference Number: 1336
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 24, 343-9 (2013)
PubMed link      E-mail link

Reference Number: 1549
Huang J, Dong B, Zhang J, Kong W, Chen Y, Xue W, Liu D, Huang Y. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma. Tumour Biol. 35, 5833-43 (2014)
PubMed link      E-mail link

Reference Number: 1729
Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther. 14, 101-10 (2015)
PubMed link      E-mail link

Leiomyosarcoma

Reference Number: 336
Xie Q, Gao CF, Shinomiya N, Sausville E, Hay R, Gustafson M, Shen Y, Wenkert D, Vande Woude GF. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 24, 3697-707 (2005)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 824
Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K, Osgood T, Coxon A, Burgess TL, Vande Woude GF. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther. 8, 2803-10 (2009)
PubMed link      E-mail link

Liver

Reference Number: 292
Wang SY, Chen B, Zhan YQ, Xu WX, Li CY, Yang RF, Zheng H, Yue PB, Larsen SH, Sun HB, Yang X. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 41, 267-73 (2004)
PubMed link      E-mail link

Reference Number: 300
Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 11, 419-30 (2004)
PubMed link      E-mail link

Reference Number: 328
Yuge K, Takahashi T, Nagano S, Terazaki Y, Murofushi Y, Ushikoshi H, Kawai T, Khai NC, Nakamura T, Fujiwara H, Kosai K. Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma. Int J Oncol. 27, 77-85 (2005)
PubMed link      E-mail link

Reference Number: 472
Son G, Hirano T, Seki E, Iimuro Y, Nukiwa T, Matsumoto K, Nakamura T, Fujimoto J. Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol. 45, 688-95 (2006)
PubMed link      E-mail link

Reference Number: 474
Nakanishi C, Moriuchi A, Ido A, Numata M, Kim ID, Kusumoto K, Hasuike S, Abe H, Nagata K, Akiyama Y, Uto H, Kataoka H, Tsubouchi H. Effect of hepatocyte growth factor on endogenous hepatocarcinogenesis in rats fed a choline-deficient L-amino acid-defined diet. Oncol Rep. 16 25-31 (2006)
PubMed link      E-mail link

Reference Number: 573
Isbert C, Ritz JP, Roggan A, Schuppan D, Ajubi N, Buhr HJ, Hohenberger W, Germer CT. Laser-induced thermotherapy (LITT) elevates mRNA expression of connective tissue growth factor (CTGF) associated with reduced tumor growth of liver metastases compared to hepatic resection. Lasers Surg Med. 39, 42-50 (2007)
PubMed link      E-mail link

Reference Number: 612
Salvi A, Arici B, Portolani N, Giulini SM, De Petro G, Barlati S. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol. 31, 451-60 (2007)
PubMed link      E-mail link

Reference Number: 645
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, Kim JH, Kim JR. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 25, 89-96 (2008)
PubMed link      E-mail link

Reference Number: 838
Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 13, 404-14 (2010)
PubMed link      E-mail link

Reference Number: 900
Singhal G, Rajeswari MR. Interaction of actinomycin D with promoter element of c-met and its inhibitory effect on the expression of c-Met. J Biomol Struct Dyn. 26, 625-36 (2009)
PubMed link      E-mail link

Reference Number: 1055
Inagaki Y, Qi F, Gao J, Qu X, Hasegawa K, Sugawara Y, Tang W, Kokudo N. Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth. Biosci Trends. 5, 52-6 (2011)
PubMed link      E-mail link

Reference Number: 1102
You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 54, 879-89 (2011)
PubMed link      E-mail link

Reference Number: 1131
Gao J, Inagaki Y, Song P, Qu X, Kokudo N, Tang W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res. 65, 23-30 (2012)
PubMed link      E-mail link

Reference Number: 1132
Huynh H, Ong R, Soo KC. Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 15, 59-7 (2012)
PubMed link      E-mail link

Reference Number: 1266
Ozen E, Gozukizil A, Erdal E, Uren A, Bottaro DP, Atabey N. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1. PLoS One. 7, e42717 (2012)
PubMed link      E-mail link

Reference Number: 1272
Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs FT, Weiss A, Miles S, Gasbarrini A, Lencioni M, Cicalese L, Sherman M, Gridelli C, Buggisch P, Gerken G, Schmid RM, Boni C, Personeni N, Hassoun Z, Abbadessa G, Schwartz B, Von Roemeling R, Lamar ME, Chen Y, Porta C. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 14, 55-63 (2013)
PubMed link      E-mail link

Reference Number: 1302
Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs. 22, 141-7 (2013)
PubMed link      E-mail link

Reference Number: 1384
Wang K1, Lim HY, Shi S, Lee J, Deng S, Xie T, Zhu Z, Wang Y, Pocalyko D, Yang WJ, Rejto PA, Mao M, Park CK, Xu J. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology. 58, 706-17 (2013)
PubMed link      E-mail link

Reference Number: 1404
Jiang HL1, Jin JZ, Wu D, Xu D, Lin GF, Yu H, Ma DY, Liang J. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. Mol Biol Rep 40, 4203-9 (2013)
PubMed link      E-mail link

Reference Number: 1491
Chen X, Ding G, Gao Q, Sun J, Zhang Q, Du L, Qiu Z, Wang C, Zheng F, Sun B, Ni J, Feng Z, Zhu J. PLoS One. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. PLos One 8, e63093 (2013)
PubMed link      E-mail link

Reference Number: 1527
Giordano S, Columbano A. Met as a therapeutic target in HCC: facts and hopes. J Hepatol. 60, 442-52 (2014)
PubMed link      E-mail link

Reference Number: 1603
Tabernero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, Baselga J A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases. Clin Cancer Res. 20, 2793-804 (2014)
PubMed link      E-mail link

Reference Number: 1631
Xiang Q, Chen W, Ren M, Wang J, Zhang H, Deng DY, Zhang L, Shang C, Chen Y. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin Cancer Res. 20, 2959-70 (2014)
PubMed link      E-mail link

Reference Number: 1743
Okusaka T, Aramaki T, Inaba Y, Nakamura S, Morimoto M, Moriguchi M, Sato T, Ikawa Y, Ikeda M, Furuse J. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors. Cancer Sci. 106, 611-7 (2015)
PubMed link      E-mail link

Reference Number: 1806
García-Vilas JA, Quesada AR, Medina MA. Damnacanthal, a noni anthraquinone, inhibits c-Met and is a potent antitumor compound against Hep G2 human hepatocellular carcinoma cells. Sci Rep. 5, 8021 (2015)
PubMed link      E-mail link

Reference Number: 1807
Kos P, Lächelt U, Herrmann A, Mickler FM, Döblinger M, He D, Krhac Levacic A, Morys S, Bräuchle C, Wagner E. Histidine-rich stabilized polyplexes for cMet-directed tumor-targeted gene transfer. Nanoscale. 7, 5350-62 (2015)
PubMed link      E-mail link

Reference Number: 1826
Zhang B, Zhang X, Zhou T, Liu J. Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. Cancer Biol Ther. 16, 215-8 (2015)
PubMed link      E-mail link

Reference Number: 1857
Steinway SN, Dang H, You H, Rountree CB, Ding W. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met Hepatocellular Carcinoma. PLoS One. 10, e0128159 (2015)
PubMed link      E-mail link

Reference Number: 1863
Ha TY, Hwang S, Moon KM, Won YJ, Song GW, Kim N, Tak E, Ryoo BY, Hong HN. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. Anticancer Res. 35, 1967-76 (2015)
PubMed link      E-mail link

Reference Number: 1880
Jiang X, Feng K, Zhang Y, Li Z, Zhou F, Dou H, Wang T. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. Oncotarget. 6, 12340-56 (2015)
PubMed link      E-mail link

Reference Number: 1898
Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, Sheehan S, Sundaram E, Karol MD, Chen J, Zhu AX. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs. 33, 128-37 (2015)
PubMed link      E-mail link

Reference Number: 1901
Wu JR, Hu CT, You RI, Ma PL, Pan SM, Lee MC, Wu WS. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One. 10, e0114495 (2015)
PubMed link      E-mail link

Reference Number: 1905
Zhang B, Zhang X, Zhou T, Liu J. Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. Cancer Biol Ther. 16, 215-8 (2015)
PubMed link      E-mail link

Lung

Reference Number: 23
Kuba, K. et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60, 6737-43 (2000).
PubMed link      E-mail link

Reference Number: 38
Fazekas, K., Raso, E., Zarandi, M., Dudas, J. & Timar, J. Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models. Anticancer Res 22, 2575-9 (2002).
PubMed link      E-mail link

Reference Number: 244
Stabile LP, Lyker JS, Huang L, Siegfried JM. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther 11:325-35 (2004).
PubMed link      E-mail link

Reference Number: 275
Tokunou M, Niki T, Eguchi K, Iba S, Tsuda H, Yamada T, Matsuno Y, Kondo H, Saitoh Y, Imamura H, Hirohashi S.  c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma.  Am J Pathol 1581451-63 (2001).
PubMed link      E-mail link

Reference Number: 298
Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther 11, 1205-14 (2004)
PubMed link      E-mail link

Reference Number: 333
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res65, 1479-88 (2005)
PubMed link      E-mail link

Reference Number: 337
Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 11, 2312-9 (2005)
PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 569
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316, 1039-43 (2007)
PubMed link      E-mail link

Reference Number: 571
Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67, 3529-34 (2007)
PubMed link      E-mail link

Reference Number: 641
Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol. 3, 331-9 (2008)
PubMed link      E-mail link

Reference Number: 656
Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, Dacic S, Luong TM, Kim KJ, Dulak AM, Siegfried JM. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther. 7, 1913-22 (2008)
PubMed link      E-mail link

Reference Number: 692
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479-87 (2008)
PubMed link      E-mail link

Reference Number: 700
Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 99, 911-22  (2008)
PubMed link      E-mail link

Reference Number: 704
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 104, 20932-7 (2007) Epub 2007 Dec 18
PubMed link      E-mail link

Reference Number: 714
Cappuzzo F, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 20, 298-304 (2009) Epub 2008 Oct 3
PubMed link      E-mail link

Reference Number: 725
Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 63, 169-79. Epub 2008 Jul 30 (2009)
PubMed link      E-mail link

Reference Number: 798
Wang X, Li K, Chen H, Wang D, Zhang Y, Bai C. Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med. 14, 833-9 (2010)
PubMed link      E-mail link

Reference Number: 838
Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 13, 404-14 (2010)
PubMed link      E-mail link

Reference Number: 911
Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J Thorac Oncol. 5, 1317-24 (2010)
PubMed link      E-mail link

Reference Number: 912
Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Mol Cancer Res. 8, 1142-51 (2010)
PubMed link      E-mail link

Reference Number: 939
Matsubara D, Ishikawa S, Sachiko O, Aburatani H, Fukayama M, Niki T. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol. 177, 2191-204 (2010)
PubMed link      E-mail link

Reference Number: 950
Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 68, 198-203 (2010
PubMed link      E-mail link

Reference Number: 951
Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, Williams BJ, Cardelli JA. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res. 15, 4885-94 (2009)
PubMed link      E-mail link

Reference Number: 959
Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem. 286, 20666-76 (2011)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 969
Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res. 16, 174-83 (2010)
PubMed link      E-mail link

Reference Number: 977
Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene. 30, 3625-35 (2011)
PubMed link      E-mail link

Reference Number: 993

Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Semin Oncol. 38, 274-83 (2011)
PubMed link      E-mail link

Reference Number: 996
Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 32, 3265-74 (2011)
PubMed link      E-mail link

Reference Number: 1002
Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs. 29, 41-51 (2011)
PubMed link      E-mail link

Reference Number: 1028
Wang ZX, Lu BB, Yang JS, Wang KM, De W. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells. J Surg Res. 171, 127-35 (2011)
PubMed link      E-mail link

Reference Number: 1030
Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 6, 1624-31 (2011)
PubMed link      E-mail link

Reference Number: 1052
Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E, Hirsch FR, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell J. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer. 105, 814-23 (2011)
PubMed link      E-mail link

Reference Number: 1053
Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 29, 3307-15 (2011)
PubMed link      E-mail link

Reference Number: 1064
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 18, 74-82 (2011)
PubMed link      E-mail link

Reference Number: 1069
Milanovic M, Radtke S, Peel N, Howell M, Carrière V, Joffre C, Kermorgant S, Parker PJ. Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid. Int J Cancer. 130, 1060-70 (2012)
PubMed link      E-mail link

Reference Number: 1074
Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res. 17, 2260-9 (2011)
PubMed link      E-mail link

Reference Number: 1078
Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 4, 146-52 (2010)
PubMed link      E-mail link

Reference Number: 1083
Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 15, 6630-8 (2009)
PubMed link      E-mail link

Reference Number: 1094
Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 89, 301-14 (2009)
PubMed link      E-mail link

Reference Number: 1099
Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafrate AJ. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 6, 942-6 (2011)
PubMed link      E-mail link

Reference Number: 1103
Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 11, 1655-62 (2011)
PubMed link      E-mail link

Reference Number: 1104
Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer. 74, 293-9 (2011)
PubMed link      E-mail link

Reference Number: 1134
Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol. 7, 272-80 (2012)
PubMed link      E-mail link

Reference Number: 1135
Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol. 7, 459-67 (2012)
PubMed link      E-mail link

Reference Number: 1158
Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320, 48-55 (2012)
PubMed link      E-mail link

Reference Number: 1159
Han SY, Lee CO, Ahn SH, Lee MO, Kang SY, Cha HJ, Cho SY, Ha JD, Ryu JW, Jung H, Kim HR, Koh JS, Lee J. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs. 30, 518-23 (2012)
PubMed link      E-mail link

Reference Number: 1224
Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 7, 1211-7 (2012)
PubMed link      E-mail link

Reference Number: 1229
Liu Y, Yang Y, Ye YC, Shi QF, Chai K, Tashiro S, Onodera S, Ikejima T. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. J Pharmacol Sci. 118, 423-32 (2012)
PubMed link      E-mail link

Reference Number: 1230
Yang M, Shan B, Li Q, Song X, Cai J, Deng J, Zhang L, Du Z, Lu J, Chen T, Wery JP, Chen Y, Li Q. Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients. Int J Cancer. 132, E74-84 (2013)
PubMed link      E-mail link

Reference Number: 1235
Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 18, 3592-602 (2012)
PubMed link      E-mail link

Reference Number: 1237
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44, 852-60 (2012)
PubMed link      E-mail link

Reference Number: 1264
Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. Expert Rev Anticancer Ther. 12, 1299-312 (2012)
PubMed link      E-mail link

Reference Number: 1265
Yano S, Takeuchi S, Nakagawa T, Yamada T. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci. 103, 1189-94 (2012)
PubMed link      E-mail link

Reference Number: 1279
Bang YJ. Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 136, 1201-4 (2012)
PubMed link      E-mail link

Reference Number: 1281
Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 181, 1034-43 (2012)
PubMed link      E-mail link

Reference Number: 1289
Voortman J, Harada T, Chang RP, Killian JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y, Giaccone G. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des. 19, 833-40 (2013)
PubMed link      E-mail link

Reference Number: 1291
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 11, 2149-57 (2012)
PubMed link      E-mail link

Reference Number: 1293
Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K. a-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Lett. 335, 472-8 (2013)
PubMed link      E-mail link

Reference Number: 1294
Landi L, Minuti G, D'Incecco A, Cappuzzo F. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Curr Opin Oncol. 25, 130-6 (2013)
PubMed link      E-mail link

Reference Number: 1301
Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 17, 1351-75 (2012)
PubMed link      E-mail link

Reference Number: 1310
Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer. 133, 505-13 (2013)
PubMed link      E-mail link

Reference Number: 1342
Ogi S1, Fujita H, Kashihara M, Yamamoto C, Sonoda K, Okamoto I, Nakagawa K, Ohdo S, Tanaka Y, Kuwano M, Ono M. Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs. Cancer Sci. 104(5):573-83 (2013)
PubMed link      E-mail link

Reference Number: 1366
Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8, e62104 (2013)
PubMed link      E-mail link

Reference Number: 1375
Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A, Xu W, Cai X, Voi M, Savagner P, Lai CJ. Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther. 12, 925-36 (2013)
PubMed link      E-mail link

Reference Number: 1402
Casaluce F1, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol. 8, 55-67 (2013)
PubMed link      E-mail link

Reference Number: 1403
Chen G1, Noor A, Kronenberger P, Teugels E, Umelo IA, De Grève J. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 8, e59708 (2013)
PubMed link      E-mail link

Reference Number: 1412
Timm A1, Kolesar JM. Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 70, 943-7 (2013)
PubMed link      E-mail link

Reference Number: 1433
Roskoski R Jr. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. Expert Opin Drug Discov. 8, 1165-79 (2013)
PubMed link      E-mail link

Reference Number: 1439
Zhang YW1, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther. 12, 1429-41 (2013)
PubMed link      E-mail link

Reference Number: 1444
Penuel E1, Li C, Parab V, Burton L, Cowan KJ, Merchant M, Yauch RL, Patel P, Peterson A, Hampton GM, Lackner MR, Hegde PS. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. Mol Cancer Ther. 12, 1122-30 (2013)
PubMed link      E-mail link

Reference Number: 1461
Yamamoto N1, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa K. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br J Cancer. 109, 2803-9 (2013)
PubMed link      E-mail link

Reference Number: 1464
Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 74, 884-95 (2014)
PubMed link      E-mail link

Reference Number: 1473
Tumati V, Kumar S, Yu L, Chen B, Choy H, Saha D. Effect of PF-02341066 and radiation on non-small cell lung cancer cells. Oncol Rep. 29, 1094-100 (2013)
PubMed link      E-mail link

Reference Number: 1485
Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS, Jeong CH. Cancer Sci. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification. Cancer Sci 105, 1245-53 (2014)
PubMed link      E-mail link

Reference Number: 1506
Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8, e62104 (2013)
PubMed link      E-mail link

Reference Number: 1508
Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 84, e525-31 (2012)
PubMed link      E-mail link

Reference Number: 1509
Koudelakova V, Kneblova M, Trojanec R, Drabek J, Hajduch M. Non-small cell lung cancer--genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 157, 125-36 (2013)
PubMed link      E-mail link

Reference Number: 1512
La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One. 8, e78656 (2013)
PubMed link      E-mail link

Reference Number: 1515
Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anticancer Drugs. 24, 1039-46 (2013)
PubMed link      E-mail link

Reference Number: 1536
Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, Barti-Juhasz H, Schönleber J, Brauswetter D, Kopper L, Urban L. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer. 83, 109-11 (2014)
PubMed link      E-mail link

Reference Number: 1540
Stutz E, Gautschi O, Fey MF, Gugger M, Tschan MP, Rothschild SI. Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology. Future Oncol. 10, 211-7 (2014)
PubMed link      E-mail link

Reference Number: 1575
Zhou YM, Liu J, Sun W. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev. 15, 1391-6 (2014)
PubMed link      E-mail link

Reference Number: 1579
Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, Uemura T, Kasai D, Miyazaki M, Niimi A. Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells. Cancer Sci. 105, 1032-9 (2014)
PubMed link      E-mail link

Reference Number: 1598
Yang X, Yang Y, Tang S, Tang H, Yang G, Xu Q, Wu J. Anti-tumor effect of polysaccharides from Scutellaria barbata D. Don on the 95-D xenograft model via inhibition of the C-met pathway. J Pharmacol Sci. 125, 255-63 (201)
PubMed link      E-mail link

Reference Number: 1599
Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS One. 8, e84700 (2013)
PubMed link      E-mail link

Reference Number: 1615
Liao ZJ, Guo YH, Zhao Z, Yao JT, Xu R, Nan KJ. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway. Int J Oncol. 45, 651-8 (2014)
PubMed link      E-mail link

Reference Number: 1618
Qu G, Liu C, Sun B, Zhou C, Zhang Z, Wang P. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. Oncol Rep. 32, 341-7 (2014)
PubMed link      E-mail link

Reference Number: 1619
Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 9, 775-83 (2014)
PubMed link      E-mail link

Reference Number: 1670
Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer. 86, 195-200 (2014)
PubMed link      E-mail link

Reference Number: 1671
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, Lipkind M, Huang J, Lazarov M, Ramakrishnan V, Amler L, Phan SC, Patel P, Peterson A, Yauch RL. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res. 20, 4488-98 (2014)
PubMed link      E-mail link

Reference Number: 1675
Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Greco A, Gramanzini M, Ortosecco G, Fonti R, Brunetti A, Del Vecchio S. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography. Clin Cancer Res. 20, 4806-15 (2014)
PubMed link      E-mail link

Reference Number: 1677
Jang WJ, Park B, Jeong GS, Hong SS, Jeong CH. SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification. Oncol Rep. 32, 2612-8 (2014)
PubMed link      E-mail link

Reference Number: 1679
Holland WS, Chinn DC, Lara PN Jr, Gandara DR, Mack PC. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 141, 615-26 (2015)
PubMed link      E-mail link

Reference Number: 1705
Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 5, 4920-8 (2014)
PubMed link      E-mail link

Reference Number: 1706
Jung SK, Lee MH, Lim do Y, Lee SY, Jeong CH, Kim JE, Lim TG, Chen H, Bode AM, Lee HJ, Lee KW, Dong Z. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth. Mol Carcinog. 54, 322-31 (2015)
PubMed link      E-mail link

Reference Number: 1707
Stabile LP, Rothstein ME, Gubish CT, Cunningham DE, Lee N, Siegfried JM. Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF. J Thorac Oncol. 9, 1285-93 (2014)
PubMed link      E-mail link

Reference Number: 1750
Yagishita S, Hamada A. Clinical pharmacology of EGFR/Met inhibitors in non-small cell lung cancer. Curr Drug Targets. 15, 1263-72 (2014)
PubMed link      E-mail link

Reference Number: 1777
Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Mol Cancer Ther. 14, 533-41 (2015)
PubMed link      E-mail link

Reference Number: 1794
Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, Ladanyi M. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 5, 842-9 (2015)
PubMed link      E-mail link

Reference Number: 1798
Ahsan A Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update. Adv Exp Med Biol. 893, 137-53 (2016)
PubMed link      E-mail link

Reference Number: 1802
Sargis RM, Salgia R Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. Am J Clin Oncol. 38, 442-7 (2015)
PubMed link      E-mail link

Reference Number: 1814
Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Mol Oncol. 9, 260-9 (2015)
PubMed link      E-mail link

Reference Number: 1816
Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs. 33, 632-40 (2015)
PubMed link      E-mail link

Reference Number: 1817
Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS One. 10, e0119832 (2015)
PubMed link      E-mail link

Lymphomas

Reference Number: 682
Accornero P, Lattanzio G, Mangano T, Chiarle R, Taulli R, Bersani F, Forni PE, Miretti S, Scuoppo C, Dastrù W, Christensen JG, Crepaldi T, Ponzetto C. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. Clin Cancer Res. 14, 2220-6 (2008)
PubMed link      E-mail link

Reference Number: 710
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 6, 3314-22 (2007)
PubMed link      E-mail link

Reference Number: 713
Ria R, Cirulli T, Giannini T, Bambace S, Serio G, Portaluri M, Ribatti D, Vacca A, Dammacco F. Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. Clin Exp Med. 8,141-5 (2008) Epub 2008 Sep 13
PubMed link      E-mail link

Reference Number: 802
Uddin S, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P, Al-Kuraya KS. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest. 90, 1346-56 (2010)
PubMed link      E-mail link

Reference Number: 1539
Heigener DF, Reck M. Crizotinib. Recent Results Cancer Res. 201, 197-205 (2014)
PubMed link      E-mail link

Reference Number: 1803
Dai L, Trillo-Tinoco J, Cao Y, Bonstaff K, Doyle L, Del Valle L, Whitby D, Parsons C, Reiss K, Zabaleta J, Qin Z. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood. 126, 2821-31 (2015)
PubMed link      E-mail link

Melanoma

Reference Number: 22
Jakubczak, J. L., LaRochelle, W. J. & Merlino, G. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo. Mol Cell Biol 18, 1275-83. (1998).
PubMed link      E-mail link

Reference Number: 38
Fazekas, K., Raso, E., Zarandi, M., Dudas, J. & Timar, J. Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models. Anticancer Res 22, 2575-9 (2002).
PubMed link      E-mail link

Reference Number: 868
Kenessey I, Keszthelyi M, Krámer Z, Berta J, Adám A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, Szokol B, Orfi L, Kéri G, Döme B, Klepetko W, Tímár J, Tóvári J. Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets. 10, 332-42 (2010)
PubMed link      E-mail link

Reference Number: 873
Yamamoto BJ, Elias PD, Masino JA, Hudson BD, McCoy AT, Anderson ZJ, Varnum MD, Sardinia MF, Wright JW, Harding JW. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther. 333, 161-73 (2010)
PubMed link      E-mail link

Reference Number: 880
Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, Salgia R. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 13, 2246-53 (2007)
PubMed link      E-mail link

Reference Number: 1139
Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, Bongarzone I, Rodolfo M. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia. 13, 1132-42 (2011)
PubMed link      E-mail link

Reference Number: 1182
Kawas LH, McCoy AT, Yamamoto BJ, Wright JW, Harding JW. Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers. J Pharmacol Exp Ther. 340, 539-48 (2012)
PubMed link      E-mail link

Reference Number: 1206
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487, 500-4 (2012)
PubMed link      E-mail link

Reference Number: 1207
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487, 505-9 (2012)
PubMed link      E-mail link

Reference Number: 1233
Samadi AK, Cohen SM, Mukerji R, Chaguturu V, Zhang X, Timmermann BN, Cohen MS, Person EA. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation. Tumour Biol. 33, 1179-89 (2012)
PubMed link      E-mail link

Reference Number: 1478
Jubb AM, Ribas A, Sosman JA, McArthur GA, Yan Y, Rost S, Zhao S, Koeppen H. Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma. Histopathology. 63, 351-61 (2013)
PubMed link      E-mail link

Reference Number: 1546
Surriga O, Rajasekhar VK, Ambrosini G, Dogan Y, Huang R, Schwartz GK. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol Cancer Ther. 12, 2817-26 (2014)
PubMed link      E-mail link

Reference Number: 1664
Etnyre D, Stone AL, Fong JT, Jacobs RJ, Uppada SB, Botting GM, Rajanna S, Moravec DN, Shambannagari MR, Crees Z, Girard J, Bertram C, Puri N. Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy. Cancer Biol Ther. 15, 1129-41 (2015)
PubMed link      E-mail link

Reference Number: 1796
Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, Mully TW, North JP, Garrido MC, Gagnon A, Vemula SS, McCalmont TH, LeBoit PE, Bastian BC. Activating MET kinase rearrangements in melanoma and Spitz tumours. Nat Commun. 27, 7174 (2015)
PubMed link      E-mail link

Mesothelioma

Reference Number: 417
Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Janne PA. Inhibition of the met receptor in mesothelioma. Clin Cancer Res. 11, 8122-30 (2005)
PubMed link      E-mail link

Reference Number: 421
Vogelzang NJ, Porta C, Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol. 32, 336-50 (2005)
PubMed link      E-mail link

Reference Number: 661
Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, Kondo Y, Osada H, Usami N, Yokoi K, Ueda Y, Yatabe Y, Ito M, Horio Y, Hida T, Sekido Y. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 30, 1097-105 (2009)
PubMed link      E-mail link

Reference Number: 725
Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 63, 169-79. Epub 2008 Jul 30 (2009)
PubMed link      E-mail link

Reference Number: 1129
Brevet M, Shimizu S, Bott MJ, Shukla N, Zhou Q, Olshen AB, Rusch V, Ladanyi M. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy. J Thorac Oncol. 6, 864-74 (2011)
PubMed link      E-mail link

Reference Number: 1702
Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One. 9(9):e105919 (2014)
PubMed link      E-mail link

Reference Number: 1756
Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells. Curr Drug Targets. 15, 1331-40 (2014)
PubMed link      E-mail link

MFH/Fibrosarcoma

Reference Number: 48
Morotti, A., Mila, S., Accornero, P., Tagliabue, E. & Ponzetto, C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21, 4885-93 (2002).
PubMed link      E-mail link

Reference Number: 918
Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, Lin YT, Wu JM, Tsai JW, Li SH, Huang HY. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol. 23, 1379-92 (2010)
PubMed link      E-mail link

Multiple Myeloma

Reference Number: 288
Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Borset M. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 10, 6686-94 (2004)
PubMed link      E-mail link

Reference Number: 513
Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, Otsuki T, Niikura T, Nukiwa T, Ikeda Y. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood. 109, 3042-9 (2007)
PubMed link      E-mail link

Reference Number: 809
Ludek P, Hana S, Zdenek A, Martina A, Dana K, Tomas B, Lucie K, Marta K, Jaroslav M, Miroslav P, Jiri V, Roman H. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol. 84, 332-6 (2010)
PubMed link      E-mail link

Reference Number: 814
Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol. 63, 587-97 (2009)
PubMed link      E-mail link

Reference Number: 1533
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 6, 92 (2013)
PubMed link      E-mail link

Reference Number: 1560
Slørdahl TS, Denayer T, Moen SH, Standal T, Børset M, Ververken C, Rø TB. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment. Eur J Haematol. 91, 399-410 (2013)
PubMed link      E-mail link

Reference Number: 1587
Patnaik A, Weiss GJ, Papadopoulos KP, Hofmeister CC, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo FC, Cotreau MM, Ramanathan RK. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. Br J Cancer. 111, 272-80 (2014)
PubMed link      E-mail link

Reference Number: 1845
Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 17, 289-300 (2015)
PubMed link      E-mail link

Nasopharyngeal

Reference Number: 967
Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK, Tsang CM, Tsao SW, Cheng SH, Ng MH, Ng YK, Lam EK, Hong B, Lo KW, Mok TS, Chan AT, Mills GB. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene. 30, 1127-34 (2011)
PubMed link      E-mail link

Reference Number: 1163
Lau PC, Wong EY. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines. Pathol Oncol Res. 18, 357-63 (2012)
PubMed link      E-mail link

Reference Number: 1448
Liu T1, Li Q2, Sun Q1, Zhang Y1, Yang H1, Wang R1, Chen L1, Wang W3. MET inhibitor PHA-665752 suppresses the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 449, 49-54 (2014)
PubMed link      E-mail link

Reference Number: 1730
Li YQ, Ren XY, He QM, Xu YF, Tang XR, Sun Y, Zeng MS, Kang TB, Liu N, Ma J MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. Cell Death Dis. 6, e1618 (2015)
PubMed link      E-mail link

Osteosarcoma

Reference Number: 411
Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, Vigna E, Naldini L, Baldini N, Ferracini R, Corso S, Giordano S, Comoglio PM, Di Renzo MF. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 66, 4750-7 (2006)
PubMed link      E-mail link

Reference Number: 1112
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi X, Hoang BH. The Wnt signaling pathway: implications for therapy in osteosarcoma. Expert Rev Anticancer Ther. 11, 1223-32 (2011)
PubMed link      E-mail link

Reference Number: 1127
Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O'Keefe RJ, Rosier RN. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res. 26, 1283-94 (2011)
PubMed link      E-mail link

Reference Number: 1231
Wang K, Zhuang Y, Liu C, Li Y. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Arch Biochem Biophys. 526, 38-43 (2012)
PubMed link      E-mail link

Ovarian

Reference Number: 826
Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer. 18, 976-84 (2008)
PubMed link      E-mail link

Reference Number: 828
Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 12, 1-10 (2010)
PubMed link      E-mail link

Reference Number: 920
Bu R, Uddin S, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, Ahmed M, Al-Kuraya KS. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest. 91, 124-37 (2011)
PubMed link      E-mail link

Reference Number: 1110
Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 17, 4042-51 (2011)
PubMed link      E-mail link

Reference Number: 1320
Surbone A, Fuso L, Passera R, Ferrero A, Marchese C, Martino C, Luchin A, Di Renzo MF, Zola P. Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications. BMC Res Notes. 5, 517 (2012)
PubMed link      E-mail link

Reference Number: 1443
Pavan S1, Musiani D, Torchiaro E, Migliardi G, Gai M, Di Cunto F, Erriquez J, Olivero M, Di Renzo MF. HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. Int J Cancer. 134, 1289-99 (2014)
PubMed link      E-mail link

Reference Number: 1459
Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 29, 2011-8 (2013)
PubMed link      E-mail link

Pancreas/Gall Bladder

Reference Number: 116
Maehara, N. et al. Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin Exp Metastasis 19, 417-26 (2002).
PubMed link      E-mail link

Reference Number: 117
Saimura, M. et al. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res 8, 3243-9 (2002).
PubMed link      E-mail link

Reference Number: 118
Tomioka, D. et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61, 7518-24 (2001).
PubMed link      E-mail link

Reference Number: 289
Lai RX, Yuan SZ, Nakamura T. [Article in Chinese] [Effect of Transferred NK4 Gene on Biological Characteristics of Human Pancreatic Cancer Cell Line SW1990.] Ai Zheng 23, 1134-8 (2004)
PubMed link      E-mail link

Reference Number: 290
Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres. Pharm Res 21, 1109-18 (2004)
PubMed link      E-mail link

Reference Number: 296
Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 64, 3215-22 (2004)
PubMed link      E-mail link

Reference Number: 297
Tanaka T, Shimura H, Sasaki T, Narumi K, Maemondo M, Nukiwa T, Matsumoto K, Nakamura T, Ikeda S. Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther 11, 431-40 (2004)
PubMed link      E-mail link

Reference Number: 366
Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene. 17, 3045-54 (1998)
PubMed link      E-mail link

Reference Number: 389
Ogura Y, Mizumoto K, Nagai E, Murakami M, Inadome N, Saimura M, Matsumoto K, Nakamura T, Maemondo M, Nukiwa T, Tanaka M. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther. 13, 520-9 (2006)
PubMed link      E-mail link

Reference Number: 390
Saito T, Tomida M. Generation of inhibitory DNA aptamers against human hepatocyte growth factor. DNA Cell Biol. 24, 624-33 (2005)
PubMed link      E-mail link

Reference Number: 391
Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 65, 7775-81 (2005)
PubMed link      E-mail link

Reference Number: 628
Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 14, 3629-37 (2007)
PubMed link      E-mail link

Reference Number: 648
Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-8 (2008)
PubMed link      E-mail link

Reference Number: 673
Egami T, Ohuchida K, Mizumoto K, Onimaru M, Toma H, Nishio S, Nagai E, Matsumoto K, Nakamura T, Tanaka M. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin Cancer Res. 14, 1859-67 (2008)
PubMed link      E-mail link

Reference Number: 838
Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 13, 404-14 (2010)
PubMed link      E-mail link

Reference Number: 934
Yasui T, Ohuchida K, Zhao M, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto K, Tanaka M. Tumor-stroma interactions reduce the efficacy of adenoviral therapy through the HGF-MET pathway. Cancer Sci. 102, 484-91 (2011)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 1068
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, Pasca di Magliano M, Simeone DM. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 141, 2218-2227.e5 (2011)
PubMed link      E-mail link

Reference Number: 1111
You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71, 4758-68 (2011)
PubMed link      E-mail link

Reference Number: 1270
Hill KS, Gaziova I, Harrigal L, Guerra YA, Qiu S, Sastry SK, Arumugam T, Logsdon CD, Elferink LA. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS One. 7, e40420 (2012)
PubMed link      E-mail link

Reference Number: 1317
Sennino B, Ishiguro-Oonuma T, Schriver BJ, Christensen JG, McDonald DM. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res. 73, 3692-703 (2013)
PubMed link      E-mail link

Reference Number: 1372
Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis. 4, e627 (2013)
PubMed link      E-mail link

Reference Number: 1408
Avan A1, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res. 73, 6745-56 (2013)
PubMed link      E-mail link

Reference Number: 1629
Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, Yan Y, Forrest WF, Wang Y, Raja R, Pilarsky C, de Jesus-Acosta A, Belvin M, Friedman LS, Merchant M, Jaffee EM, Zheng L, Koeppen H, Hoeflich KP. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol. 234, 502-13 (2014)
PubMed link      E-mail link

Reference Number: 1736
Yan HH, Jung KH, Son MK, Fang Z, Kim SJ, Ryu YL, Kim J, Kim MH, Hong SS. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Oncotarget. 5, 9150-68 (2014)
PubMed link      E-mail link

Reference Number: 1872
Chen HM, Tsai CH, Hung WC. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Oncotarget. 6, 14940-52 (2015)
PubMed link      E-mail link

Prostate

Reference Number: 221
Davies, G. et al. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer 106:348-54 (2003).
PubMed link      E-mail link

Reference Number: 293
Davies G, Watkins G, Mason MD, Jiang WG. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells. Prostate 60, 317-24 (2004)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link      E-mail link

Reference Number: 505
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol. 30, 521-9 (2007)
PubMed link      E-mail link

Reference Number: 688
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 14, 7385-90 (2008)
PubMed link      E-mail link

Reference Number: 705
Fan S, Meng Q, Laterra JJ, Rosen EM. Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem. 284, 7561-77 (2009) Epub 2008 Dec 1
PubMed link      E-mail link

Reference Number: 728
Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther. 9, 1554-61 (2010)
PubMed link      E-mail link

Reference Number: 936
Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 10, 556 (2010)
PubMed link      E-mail link

Reference Number: 942
McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2, 673-82 (2009)
PubMed link      E-mail link

Reference Number: 1042
Aftab DT, McDonald DM. MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol. 13, 703-9 (2011)
PubMed link      E-mail link

Reference Number: 1107
Elnagar AY, Sylvester PW, El Sayed KA. (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med. 77, 1013-9 (2011)
PubMed link      E-mail link

Reference Number: 1123
Chang HY, Kao MC, Way TD, Ho CT, Fu E. Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin. J Agric Food Chem. 59, 5357-63 (2011)
PubMed link      E-mail link

Reference Number: 1209
Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 20, 1677-84 (2011)
PubMed link      E-mail link

Reference Number: 1222
Dai Y, Siemann DW. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer. 12, 198 (2012)
PubMed link      E-mail link

Reference Number: 1298
Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 63, 309-20 (2013)
PubMed link      E-mail link

Reference Number: 1326
Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 19, 215-24 (2013)
PubMed link      E-mail link

Reference Number: 1510
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One. 8, e78881 (2013)
PubMed link      E-mail link

Reference Number: 1572
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One. 8, :e78881 (2013)
PubMed link      E-mail link

Rhabdomyosarcoma

Reference Number: 583
Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O, Majka M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs. 18, 1173-81 (2007)
PubMed link      E-mail link

Reference Number: 1126
Hou J, Dong J, Sun L, Geng L, Wang J, Zheng J, Li Y, Bridge J, Hinrichs SH, Ding SJ. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274. J Transl Med. 9, 64 (2011)
PubMed link      E-mail link

Reference Number: 1245
Chadalapaka G, Jutooru I, Sreevalsan S, Pathi S, Kim K, Chen C, Crose L, Linardic C, Safe S. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors. Int J Cancer. 132, 795-806 (2013)
PubMed link      E-mail link

Reference Number: 1373
Houghton PJ, Kurmasheva RT, Kolb EA, Wu J, Gorlick R, Maris JM, Smith MA. Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 61, 380-2 (2014)
PubMed link      E-mail link

Reference Number: 1822
Ferguson M, Hingorani P, Gupta AA. Emerging molecular-targeted therapies in early-phase clinical trials and preclinical models. Am Soc Clin Oncol Educ Book. 420-4 (2013)
PubMed link      E-mail link

Synovial Sarcoma

Reference Number: 1517
Yasui H1, Naka N2, Imura Y3, Outani H3, Kaneko K3, Hamada K3, Sasagawa S4, Araki N5, Ueda T6, Itoh K4, Myoui A3, Yoshikawa H3. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001. Cancer Lett. 347, 114-22 (2014)
PubMed link      E-mail link

Thyroid

Reference Number: 565
Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A, Alzahrani A, Ahmed M, Al-Sanea O, Uddin S, Al-Kuraya KS. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol. 213, 190-9 (2007)
PubMed link      E-mail link

Reference Number: 694
Chattopadhyay C, El-Naggar AK, Williams MD, Clayman GL. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck. 30, 991-1000 (2008)
PubMed link      E-mail link

Reference Number: 1130
Almeida MQ, Hoff AO. Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma. Curr Opin Oncol. 24, 229-34 (2012)
PubMed link      E-mail link

Reference Number: 1186
Bu R, Uddin S, Ahmed M, Hussain AR, Alsobhi S, Amin T, Al-Nuaim A, Al-Dayel F, Abubaker J, Bavi P, Al-Kuraya KS. c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death. Mol Med. 18, 167-77 (2012)
PubMed link      E-mail link

Reference Number: 1545
Zhou Y, Zhao C, Gery S, Braunstein GD, Okamoto R, Alvarez R, Miles SA, Doan NB, Said JW, Gu J, Phillip Koeffler H. Off-target effects of c-MET inhibitors on thyroid cancer cells. Mol Cancer Ther. 13, 134-43 (2014)
PubMed link      E-mail link

Reference Number: 1559
Bentzien F, Zuzow M, Heald N, Gibson A, Shi Y, Goon L, Yu P, Engst S, Zhang W, Huang D, Zhao L, Vysotskaia V, Chu F, Bautista R, Cancilla B, Lamb P, Joly AH, Yakes FM. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid. 23, 1569-77 (2013)
PubMed link      E-mail link

Wilms' Tumor

Reference Number: 375
Pinthus JH, Sheffer Y, Nagler A, Fridman E, Mor Y, Genina O, Pines M. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression. J Urol. 174, 1527-31 (2005)
PubMed link      E-mail link